Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
COLL | US
2.65
6.76%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
04/10/2024
41.86
40.25
42.23
39.84
Collegium Pharmaceutical Inc. a specialty pharmaceutical company develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily around-the-clock long-term opioid treatment; Nucynta ER and Nucynta IR which are extended-release and immediate-release formulations of tapentadol; Belbuca a buccal film that contains buprenorphine; and Symproic an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals Inc. and changed its name to Collegium Pharmaceutical Inc. in October 2003. Collegium Pharmaceutical Inc. was incorporated in 2002 and is headquartered in Stoughton Massachusetts.
View LessPositive Momentum
Strength based on increasing price with high volume
Strong Operating Margin (> 25%)
Strong Sharpe Ratio (> 1.2)
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
42.9%1 month
35.1%3 months
41.7%6 months
44.1%14.38
5.71
5.69
2.58
0.53
4.25
2.64
-
347.36M
1.35B
1.35B
-
32.68
52.30
7.20
47.87
21.77
24.45
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
5.02
Range1M
7.16
Range3M
10.97
Rel. volume
1.34
Price X volume
23.24M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Tilray Inc | TLRY | Drug Manufacturers-Specialty & Generic | 1.69 | 1.42B | 0.60% | n/a | 11.25% |
OPKO Health Inc | OPK | Drug Manufacturers-Specialty & Generic | 1.49 | 1.03B | -1.97% | n/a | 19.31% |
Evolus Inc | EOLS | Drug Manufacturers-Specialty & Generic | 16.34 | 1.03B | -4.67% | n/a | 656.27% |
PetIQ Inc | PETQ | Drug Manufacturers-Specialty & Generic | 30.87 | 923.02M | 0.13% | 83.11 | 178.54% |
Phibro Animal Health Corporation | PAHC | Drug Manufacturers-Specialty & Generic | 21.31 | 863.13M | -2.07% | 367.83 | 204.74% |
Pacira Pharmaceuticals Inc | PCRX | Drug Manufacturers-Specialty & Generic | 16.515 | 761.79M | 6.34% | 10.85 | 73.76% |
Ironwood Pharmaceuticals Inc | IRWD | Drug Manufacturers-Specialty & Generic | 4.3 | 693.71M | 0.94% | 50.25 | -199.01% |
Radius Health Inc | RDUS | Drug Manufacturers-Specialty & Generic | 17.9 | 506.39M | -4.48% | n/a | 0.00% |
Canopy Growth Corporation | CGC | Drug Manufacturers-Specialty & Generic | 4.42 | 495.19M | 0.00% | n/a | 117.00% |
Aquestive Therapeutics Inc | AQST | Drug Manufacturers-Specialty & Generic | 4.95 | 450.75M | 3.34% | n/a | -329.45% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Interface Inc | TILE | Textile Manufacturing | 18.13 | 1.06B | -0.28% | 16.28 | 106.26% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Ennis Inc | EBF | Building Products & Equipment | 24.31 | 631.67M | 2.36% | 15.15 | 2.42% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 4.25 | 17.21 | Cheaper |
Ent. to Revenue | 2.64 | 334.38 | Cheaper |
PE Ratio | 14.38 | 26.92 | Cheaper |
Price to Book | 5.69 | 12.15 | Cheaper |
Dividend Yield | - | 2.77 | - |
Std. Deviation (3M) | 41.75 | 68.34 | Lower Risk |
Debt to Equity | 2.58 | -1.00 | Expensive |
Debt to Assets | 0.53 | 0.48 | Par |
Market Cap | 1.35B | 5.31B | Emerging |